Global Rare Haematology Market is segmented By Product Class (Recombinant factor, Plasma-derived factors, Extended Half-Life), By Indication (Hemophilia A, Hemophilia A with Inhibitors, Hemophilia B, Acquired Hemophilia A, von Willebrand disease), By Patient Age-Group (Pediatrics (0-17), Adults (18+)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
The Global Rare Haematology Market is expected to grow at a high CAGR during the forecasting period (2022-2029).
- Rare hematological diseases fall into many subcategories, including anemia-type red blood cell conditions, white blood cell dysfunctions associated with various malignancies, immuno-disorders, platelet-based abnormalities that affect coagulation, and plasma-based issues (such as hemophilia A and B, von Willebrand disease).
- Globally, the Rare Hematology market was estimated at USD 10 billion in 2015 and is expected to reach USD 13 billion by 2020. The market is large and growing primarily led by Hemophilia.
Market Growth and Trends
- The global incidence of hemophilia is not well known, but it is estimated that more than 400,000 people are living with hemophilia A and B.
- Approximately 75% of people with hemophilia around the globe still receive inadequate treatment or have no access to treatment. This presents a tremendous market opportunity, thus driving market growth in the future.
- On the contrary, the inadequacy of data due to limited support from disease-specific foundations inhibits market growth.
- However, there is still a substantial unmet need for new therapies that require significantly less frequent infusions and do not promote inhibitor formation.
- Global Rare Hematology market report segments the market by product class, by indication, by age, and by region.
- Based on product class, the market is classified into Recombinant factors, Plasma-derived factors, and Extended Half-Life clotting factors.
- The recombinant factors segment is projected to witness the highest revenue growth, garnering more than USD 4 billion by 2022.
- Based on the indication, the market is segmented into Hemophilia A, Hemophilia A with Inhibitors, Hemophilia B, Acquired Hemophilia A, and von Willebrand disease.
- The market is led by Hemophilia A segment.
- Based on the patient age group, the market is segmented into adults (18+) and pediatrics (0-17).
- Adults account for 75% of the market.
- Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
- Globally North America is the largest market for Rare Hematology Treatment with the majority of demand arising from the US.
- The US hemophilia drug market, which serves about 20,000 patients, is worth USD 4 billion a year.
Market Scope of the Report
By Product Class
- Recombinant factor
- Plasma-derived factors
- Extended Half-Life
- Hemophilia A
- Hemophilia A with Inhibitors
- Hemophilia B
- Acquired Hemophilia A
- von Willebrand disease
By Patient Age-group
- Pediatrics (0-17)
- Adults (18+)
- Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
- Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
- North America (The USA, Canada, Mexico)
- South America (Brazil, Argentina, Rest of South America)
- Rest of the World
- The report also profiles the following companies in the Rare Hematology Treatment market – Biogen Inc., Shire plc, Bayer Healthcare AG, Novo Nordisk A/S, Pfizer Inc., CSL Behring LLC, Celgene Corporation, Amgen Inc. and others.
Sickle Cell Treatment Market
Serum Separation Gel Market
Allogeneic Stem Cells Market